More stories

  • in

    Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump

    Johnson & Johnson reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations.
    Sales in the company’s pharmaceutical and medical devices businesses surged.
    For the full year 2024, J&J is forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share. 

    The stock trading graph of Johnson & Johnson is seen on a smartphone screen.
    Rafael Henrique | SOPA Images | LightRocket | Getty Images

    Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations as sales in the company’s pharmaceutical and medical devices businesses surged.
    J&J also provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share. 

    Here’s what J&J reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

    Earnings per share: $2.29 adjusted vs. $2.28 expected
    Revenue: $21.40 billion vs. $21.01 billion expected

    J&J, whose financial results are considered a bellwether for the broader health sector, booked $21.40 billion in total sales for the final three months of 2023, up 7.3% from the same quarter in 2022. 
    The pharmaceutical giant reported net income of $4.13 billion, or $1.70 per share during the quarter. That compares with net income of $3.23 billion, or $1.22 per share, for the year-ago period. 
    Excluding certain items, adjusted earnings per share were $2.29 for the fourth-quarter of 2023.
    The results come six months after J&J completed its separation from its consumer health unit Kenvue, the company’s biggest shake-up in its nearly 140-year history. J&J is now zeroing in on its pharmaceutical and medical devices divisions to drive growth. 

    Segment results

    J&J’s medical devices business generated sales of $7.67 billion, up 13.3% from the fourth quarter of 2022. Wall Street was expecting revenue of $7.50 billion, according to StreetAccount.
    J&J said its acquisition of Abiomed, a cardiovascular medical technology company, in December fueled the year-over-year rise.
    The company said growth also came from electrophysiological products, which evaluate the heart’s electrical system and help doctors understand the cause of abnormal heart rhythms.
    Wound closure products and devices for orthopedic trauma, or serious injuries of the skeletal or muscular system, contributed, along with contact lenses.
    J&J is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic. The company expects that high demand to “follow through” in 2024, CFO Joseph Wolk said on CNBC’s “Squawk Box” Tuesday.
    Meanwhile, J&J reported $13.72 billion in pharmaceutical sales, marking 4.2% year over year growth. Excluding sales of its unpopular Covid vaccine, the pharmaceutical division raked in $13.68 billion. 
    It was the third quarter without any U.S. sales from J&J’s Covid vaccine, which brought in $44 million in international revenue.
    Wall Street was expecting sales of $13.44 billion for the business segment, according to StreetAccount. The business, also known as “Innovative Medicine,” is focused on developing drugs across different disease areas.
    J&J said growth in the division was driven by sales of Darzalex, a biologic for the treatment of multiple myeloma, along with Erleada, a prostate cancer treatment, and other oncology treatments. 
    J&J’s blockbuster drug Stelara, which is used to treat several chronic and potentially disabling conditions such as Crohn’s disease, also contributed to growth. J&J began to lose patent protections on Stelara late last year, which opened up the door for cheaper biosimilar competitors to enter the market. But the company has bought itself more time: J&J has inked settlement agreements with Amgen and other drugmakers to delay the launch of some Stelara copycats to 2025. 
    J&J said growth in the pharmaceutical segment was partially offset by a decline in sales of its prostate cancer drug Zytiga and blood cancer drug Imbruvica, which is co-marketed by AbbVie. Both Imbruvica and Stelara will be subject to the first round of Medicare drug price negotiations under the Inflation Reduction Act. 

    Medicare negotiations

    J&J will soon begin price talks with the federal Medicare program over Stelara as well as blood thinner Xarelto.
    President Joe Biden’s Inflation Reduction Act, which passed in 2022, empowered Medicare to negotiate down drug prices for the first time in the program’s six-decade history. J&J signed an agreement to participate in the price talks in October, even after it sued the Biden administration to halt the process in July.
    The negotiated prices for the drugs will go into effect in 2026.
    The fourth-quarter results also come amid investor concern over the thousands of lawsuits claiming that J&J’s talc-based products were contaminated with the carcinogenic asbestos and caused ovarian cancer and several deaths.
    Those products, including J&J’s namesake baby powder, now fall under Kenvue. But J&J will assume all talc-related liabilities that arise in the U.S. and Canada.
    In 2021, J&J offloaded its talc liabilities into a new subsidiary, LTL Management, which immediately filed for Chapter 11 bankruptcy protection. But a federal bankruptcy judge in July rejected J&J’s second attempt to resolve those lawsuits in bankruptcy. J&J has said LTL Management intends to appeal the decision.
    J&J will hold a conference call with investors at 8:30 a.m. ET.
    This story is developing. Please check back for updates. More

  • in

    Founders of Wise and Skype raise $436 million to build tech giants in Europe

    Plural, a venture firm set up by the founders of Wise, Skype and Songkick, raised 400 million euros ($436.4 million) for a new fund.
    Plural II will invest mainly in European tech, seeking to find innovative names that haven’t been discovered by mainstream funds like Atomico.
    Plural co-founder Taavvet Hinrikus, formerly of Wise, said his fund is different from competitors as it was started by entrepreneurs with “scar tissue.”

    The partners of European venture capital firm Plural, from left to right: Ian Hogarth, Taavet Hinrikus, Carina Namih, Sten Tamkivi and Khaled Helioui.

    The founders of Wise, Skype and Songkick have raised 400 million euros ($436.4 million) for a new fund to back technology startups in Europe. It seeks to compete with established funds like Atomico, Balderton Capital and Creandum with its founder-led focus.
    Plural Fund II, the firm’s second to date, arrives just 18 months after the firm raised its last fund, a 250 million-euro vehicle. Its co-founders include Taavet Hinrikus, co-founder of fintech firm Wise, Ian Hogarth, co-founder of concert discovery service Songkick, Sten Tamkivi, co-founder of communications platform Skype, and Khaled Helioui, former CEO of Bigpoint Games.

    Hinrikus told CNBC that Plural could serve as a better partner to startups in Europe than most venture capital funds, given that it was started by people with the “scar tissue” of proven entrepreneurs. Only 8% of VCs in Europe are former founders, he says, much lower than the 60% in the United States.
    “If we look at a lot of VC funds, you have lots of people who have done great work with spreadsheets, not with startup life,” Hinrikus told CNBC in an interview. “In our case, it is seen as a core criteria for choosing our partners that they’re totally unemployable.”
    “It feels like it’s world war three, and we’re in the trenches together as one of the founders. So, if we look at the track record, and our ability to get the deals done, I think that all seems to say that this is really missing in Europe,” Hinrikus added.
    Plural raised the funds from a mix of limited partners, including British and American university endowments, U.S. foundations and insurers, strategic family offices in Europe and the United States. The firm said it saw “significant appetite” from LPs — limited partners, the institutional backers of venture funds — for its new fund and exceeded its own fundraising target, despite being in the “toughest environment” for raising a fund.
    “The fact that, in a difficult fundraising environment, we’ve been able to raise a fund of this scale, with a huge amount of appetite from LPs, just shows you that some of the most sophisticated investors in the world are really recognising the opportunity in Europe, and really want to see a fund the shape of Plural,” Carina Namih, partner at Plural, told CNBC in an interview.

    “I think it’s a real testament against the sort of macro backdrop that we’ve raised a fund of this size and scale so quickly,” she added.

    The ‘unemployables’

    Plural plans to invest at a pace of two to three investments per investor per year with its new fund. The firm has five partners in total, whom it dubs the “unemployables,” owing to the fact that they wouldn’t readily join a VC firm, or be employable at a startup. Each of the partners is an active angel investor.
    Plural has made 27 investments in total, backing companies including law-focused artificial intelligence firm Robin AI, nuclear fusion power plant developer Proxima Fusion, and most recently drug discovery platform Sano Genetics. Its largest sectors by investment are AI (31%), frontier technology (16%), and climate and energy (14%).

    Hinrikus said Plural isn’t interested in finding the next major software-as-a-service name in Europe, referring to companies that make software for businesses to ease the burden of storing data, accessing infrastructure, and carrying out data analytics. It’s more interested in deep tech, focusing on founders looking to solve fundamental scientific problems around energy, unlock AI “superpowers,” and make groundbreaking progress in health care.

    Building tech giants in Europe

    Plural says it wants to build technology giants in Europe, identifying winners in emerging categories that other funds may tend to ignore, such as deep tech and clean tech.
    Carina Namih, a biotechnology entrepreneur-turned-partner at Plural, said she wouldn’t be surprised to see major technology names on a par with U.S. and Chinese giants start to emerge in Europe in the not-too-distant future.
    She noted technological breakthroughs are happening much faster now, boosted by key developments around AI and more established pools of capital. 
    “Look at how quickly OpenAI burst onto the scene with ChatGPT,” she said, adding it’s taking shorter amounts of time for new technologies to hit major milestones. “Clearly, the big tech companies have a lot of advantages and are entrenched in many ways. But I think now is a time more than ever, where new players and emerging players can come in and dominate entirely new spaces that didn’t exist a year ago.”
    Namih previously worked on applying AI to mRNA-based medicine at her former startup HelixNano.
    Plural’s new fund launch adds to the wave of startup activity that’s been happening in Europe in the last decade or so. 
    A report from venture capital firm Accel late last year showed that $1 billion-plus unicorn firms often serve as catalysts for startup creation, with 1,451 new startups being founded by former employees of European and Israeli unicorns.
    Of that new batch of startups, a great deal of them tend to come from fintechs, according to the report, with 70 fintech unicorns producing 423 startups.
    “In the last 10 years, the whole ecosystem really has become an ecosystem, whereas before, we were just wild game hunting,” Harry Nelis, partner at Accel, told CNBC. “There was one here, one there, there was no ecosystem.”
    “It’s a lot easier to start a company than before. The engineering has been done before, the marketing has been done before,” he added. “That is a flywheel that we have never had in Europe, that we now do have.” More

  • in

    World’s largest hedge funds record bumper year of profits, research shows

    The world’s top hedge funds raked in record profits last year amid a resurgence in stock markets, new analysis showed.
    The 20 leading fund managers made $67 billion in investor profits in 2023, up from the $65 billion recorded during the pandemic-era rally of 2021.
    Overall, the fund management industry recorded gains of $218 billion after fees, according to estimates from LCH Investments .

    Signage for Citadel Investment Group LLC hangs outside their office in Chicago, Illinois, U.S.
    Bloomberg | Getty Images

    The world’s top hedge funds raked in record profits last year amid a resurgence in stock markets, new analysis showed.
    The 20 leading fund managers made $67 billion in investor profits in 2023, up from the $65 billion recorded during the pandemic-era rally of 2021, according research Monday from LCH Investments, a fund of hedge funds.

    Overall, the fund management industry recorded gains of $218 billion after fees, according to LCH Investments estimates.
    The top funds — identified as those which have performed best in dollar terms since their inception — accounted for around one-third of annual profits last year, despite managing less than a fifth (19%) of the industry’s assets.
    Included among the best performers were Christopher Hohn’s TCI, Ken Griffin’s Citadel and Andreas Halvorsen’s Viking.

    Top 20 managers by 2023 profits

    Firm
    Assets (billion)
    Net profits since inception (billion)
    2023 profits (billion)
    Launch year

    TCI
    $50
    $41.3
    $12.9
    2004

    Citadel
    $56.8
    $74
    $8.1
    1990

    Viking
    $30.5
    $40.9
    $6
    1999

    Millennium
    $61.9
    $56.1
    $5.7
    1989

    Elliott
    $62.2
    $47.6
    $5.5
    1977

    DE Shaw
    $43.8
    $56.1
    $4.2
    1988

    Lone Pine
    $15.9
    $35.6
    $4.2
    1996

    Baupost
    $27.4
    $37
    $3.8
    1983

    Pershing Square
    $17.9
    $18.8
    $3.5
    2004

    SAC/Point72
    $31
    $33
    $3
    1992

    Appaloosa
    $17
    $35
    $2.7
    1993

    Farallon
    $40.4
    $35.7
    $2.6
    1987

    Och Ziff/Sculptor
    $28.7
    $32.2
    $2.3
    1994

    Egerton
    $14
    $23.9
    $2.3
    1995

    David Kempner
    $37
    $21
    $1.8
    1983

    King Street
    $9.5
    $19.5
    $0.9
    1995

    Brevan Howard
    $35.6
    $28.5
    $0.4
    2003

    Caxton
    $13.4
    $19.5
    $-0.3
    1983

    Bridgewater
    $72.5
    $55.8
    $-2.6
    1975

    Soros
    N/A
    $43.9
    N/A
    1973

    Source: LCH Investments

    LCH Investments’ director and head of research, Brad Amiee, said that the leading funds were buoyed by the stock market’s “fantastic run” in 2023. However, he added that many also showcased especially savvy stock selection strategies.
    “You could argue that, since shorting is such a challenging sub-strategy, keeping things long-biased and having a concentrated portfolio of high quality positions has been the way to go,” Amiee told the Financial Times.

    TCI, the top ranking fund, recorded investor profits of $12.9 billion and ended last year up 33%, beating the S&P 500’s 24% gain.
    Included in its largest holders were Alphabet, Canadian National Railway, Visa and General Electric.
    Citadel, which ranked second in 2023, made $8.1 billion in profits after bringing in a record-breaking $16 billion in 2022. Its $74 billion in gains since inception rank it as the most successful hedge fund in history.
    The research also found that the top 20 funds have made a combined $755.4 billion in profits since inception, well above the $655.5 billion in total managed assets.
    A hedge fund is a limited partnership of private investors whose money is managed by fund managers. Hedge funds are typically known for investing in higher risk and more non-traditional assets compared to mutual funds. More

  • in

    United Airlines forecasts first-quarter loss due to Boeing 737 Max 9 grounding

    The FAA grounded Boeing 737 Max 9 aircraft earlier this month after a door plug blew out during an Alaska Airlines flight.
    United said it expects a quarterly loss of at least 35 cents a share due to the grounding.
    The first-quarter warning from United comes after a relatively strong holiday period.

    A United Airlines Boeing 737 Max 9 aircraft lands at San Francisco International Airport on March 13, 2019.
    Justin Sullivan | Getty Images

    United Airlines on Monday forecast a first-quarter loss due to the Federal Aviation Administration’s grounding of Boeing 737 Max 9 planes this month after a part blew out during an Alaska Airlines flight operated with that type of aircraft.
    United expects to post an adjusted loss of between 35 cents and 85 cents a share for the first three months of the year, it said in a filing. The forecast is the first indication for investors of the financial damage caused by the FAA’s grounding of the planes, issued a day after the incident on Alaska Airlines Flight 1282 on Jan. 5.

    United has 79 of the aircraft in its fleet, more than any other carrier, followed by Alaska. United said Monday it expects the planes to remain grounded through Jan. 26, though its forecast assumes it won’t be able to fly the planes at all this month.
    Both airlines have canceled hundreds of flights this month while the planes remain grounded for inspection. The more common Boeing 737 Max 8, which is in fleets at United, American and Southwest, isn’t affected by the grounding order.
    United said it expects unit costs, excluding fuel, to be up mid-single-digit percentage points in the first quarter from last year, three points of that impact coming from the Max grounding. It forecast flat unit revenues for the first three months of the year.
    The first-quarter warning from United comes after a relatively strong holiday period, though airlines have faced several winter storms in the first few weeks of January.
    United shares were up more than 6% in after-hours trading.

    For the last three months of 2023, United posted net income of $600 million, down nearly 29% from a year ago. Revenue came in at $13.63 billion, which was up almost 10% from a year earlier and ahead of analysts’ estimates. Adjusting for one-time items, United’s fourth-quarter earnings of $2 a share fell from $2.46 a year earlier.
    Here’s what United reported in the fourth quarter compared to what Wall Street expected, based on average estimates compiled by LSEG, formerly known as Refinitiv:

    Adjusted earnings per share: $2.00 vs. an expected $1.69
    Total revenue: $13.63 billion vs. an expected $13.54 billion

    United hit its full-year adjusted earnings target of between $10 and $12 a share, posting $10.05 for the full-year 2023.
    “Despite unpredictable headwinds, we delivered on our ambitious EPS target that few thought possible — and set new operational records for our customers,” said United Airlines CEO Scott Kirby in an earnings release.
    The airline touted strong travel demand late last year and solid bookings so far this year. For the full-year 2024, United forecast adjusted earnings of between $9 and $11 a share, within analysts’ estimates.
    United executives are holding an earnings call at 10:30 a.m. ET on Tuesday when they are likely to face questions about compensation from Boeing for the grounding. Alaska reports before the market opens on Thursday, and Boeing is scheduled to report results Jan. 31.Don’t miss these stories from CNBC PRO: More

  • in

    Watchdog report is critical of former Fed officials in stock trading controversy

    A report released Monday by the Fed’s Office of Inspector General takes issue with trades made by former regional presidents Robert Kaplan of Dallas and Eric Rosengren of Boston.
    The report concludes that their actions resulted in conflicts of interest that raised issues over impartiality and the proper conduct of central bank officials.

    The Marriner S. Eccles Federal Reserve building during a renovation in Washington, DC, US, on Tuesday, Oct. 24, 2023.
    Valerie Plesch | Bloomberg | Getty Images

    A watchdog review into market trading from two former high-ranking Federal Reserve officials criticizes their actions but does not accuse either of doing anything illegal.
    The report released Monday by the Fed’s Office of Inspector General takes issue with trades made by former regional presidents Robert Kaplan of Dallas and Eric Rosengren of Boston.

    Both men left their posts in September 2021 — Kaplan to early retirement and Rosengren for medical reasons — amid criticism over trading that ultimately saw Fed Chair Jerome Powell and Governor Richard Clarida come under question along with Atlanta Fed President Raphael Bostic.
    Revelations showed that some Fed officials engaged in market trading at a time when they also were considering important and delicate policy matters in the early days of the Covid pandemic in 2020. The Fed ultimately slashed interest rates and launched a bevy of lending and liquidity programs that helped prop up financial markets as the pandemic crushed the U.S. economy.
    While Clarida is mentioned in the OIG report, the details focus on Kaplan and Rosengren’s actions. The report concludes that their actions resulted in conflicts of interest that raised issues over impartiality and the proper conduct of central bank officials.
    CNBC has reached out to both former officials for comment. Kaplan, who traded millions in stocks and options and other securities, has said that his actions were in compliance with standards in place at the time.
    With regard to Rosengren, the report faults him for not disclosing multiple trades on his 2020 ethics forms. Moreover, the report noted “multiple discrepancies” in brokerage statements and trading data.

    Trades he made regarding real estate investment trusts at a time when the Fed was buying mortgage-backed securities “create an ‘appearance of a conflict of interest’ that could cause a reasonable person to question Mr. Rosengren’s impartiality under FRB Boston’s code of conduct,” the report said.
    On Kaplan, the report states that the OIG “did not find that his trading activities violated laws, rules, regulations, or policies related to trading activities as investigated by our office.”
    However, the OIG faults Kaplan for not disclosing specific information regarding the selling of stock option contracts.
    “This lack of information, in our opinion, did not support public confidence in the impartiality and integrity of the policymakers and senior staff carrying out the public mission of the [Federal Open Market Committee’s] work, especially during this critical time period when the Federal Reserve was taking monetary policy actions to address the effects of the COVID-19 pandemic on the U.S. economy,” the report stated.
    There is a notation that Kaplan and the Dallas Fed were not specific in the disclosures because they “determined that this approach was permissible because it was consistent with Chair Powell’s reporting” on his disclosure forms.
    Since the controversy, the Fed has revamped its trading rules and now prohibits officials from owning stocks, bonds and cryptocurrencies.
    The new rules “aim to support public confidence in the impartiality and integrity of the Committee’s work by guarding against even the appearance of any conflict of interest,” said a statement issued when the Fed made the changes in February 2022. More

  • in

    Oatly shares pop as oat milk maker brings dairy-free flavors to Carvel ice cream shops

    Oatly and Carvel will partner to add oat milk-based items at the chain’s ice cream stores nationwide.
    The partnership is a boon for Oatly, which has seen its share price crumble since its 2021 initial public offering.
    The oat milk-based products will be available at nearly 300 Carvel stores located in 18 states.

    Containers of Oatly frozen desserts are displayed on a shelf at a Whole Foods store in San Rafael, California, on Nov. 15, 2021.
    Justin Sullivan | Getty Images

    Oatly and Carvel said on Monday that they will partner to add oat milk-based items at the chain’s ice cream stores nationwide.
    The agreement is a boon for Oatly, which has struggled to recapture the enthusiasm investors had for the plant-based milk company when it made its stock market debut in 2021. Its shares jumped about 7% in Monday trading.

    Oatly, a Swedish company with a roughly $657 million market cap, saw its stock trade around $1.12 a share Monday. The company’s financial performance has repeatedly disappointed Wall Street since its initial public offering, erasing its share value since the day it opened trading at $22.12 per share in 2021.
    Carvel, a chain known for its soft serve, will add five new plant-based desserts to its menu as part of the partnership. The Oatly flavors will be available at nearly 300 of Carvel’s stores in 18 states.
    The Oatly products will include strawberry soft serve and scooped cookies and cream and chocolate peanut butter flavors, along with cakes.
    Oatly said the partnership will help the ice cream shop chain serve people with dairy allergies or dietary restrictions. More consumers have embraced plant-based milk in recent years, and oat milk has started to make up a larger share of that segment.
    Jim Salerno, chief brand officer at Carvel, added in a statement that “Oatly is the latest way we are breaking through to bring our guests a new offering we know there is a lot of excitement behind.”Don’t miss these stories from CNBC PRO: More

  • in

    As China’s markets plunge, what alternatives do investors have?

    Every day brings more misery for China’s foreign investors. Some are most worried by China’s souring relations with Western governments. Others fret about the unprecedented slump in the country’s property market. Many are simply tired of losing money. On January 22nd the CSI 300 index of Chinese shares dropped by 1.6%; it is now nearly a quarter below its level of a year ago. Meanwhile, Hong Kong’s Hang Seng index fell by 2.3% on the day, and is more than a third below its level at the start of 2023.Heady optimism about China Inc. is an increasingly distant memory. Just five years ago investors clamoured for exposure to the country’s growth miracle and sought diversification from rich-world markets, which often move in lockstep. Providers of the world’s most important stock indices—FTSE and MSCI—were making adjustments accordingly. Between 2018 and 2020 Chinese stocks listed onshore, known as A-shares, were added to the benchmark emerging-markets index.image: The EconomistAt their peak in 2020 Chinese firms made up over 40% of the index by value. In 2022 foreigners owned $1.2trn-worth of stocks, or 5-10% of the total, in mainland China and Hong Kong. One investment manager describes the challenge of investing in emerging markets while avoiding China as like investing in developed markets while avoiding America. So how will investors do it? And where will their money flow instead?Some investment firms are eager to help. Jupiter Asset Management, Putnam Investments and Vontobel all launched actively managed “ex-China” funds in 2023. An emerging-market, ex-China, exchange-traded fund (etf) issued by BlackRock is now the fifth-largest emerging-market equity etf, with $8.7bn in assets under management, up from $5.7bn in July.A handful of large emerging stockmarkets are benefiting. Money has poured into India, South Korea and Taiwan, whose shares together make up more than 60% of ex-China emerging-market stocks. These markets received around $16bn in the final three months of 2023. Squint and the countries together look something like China: a fast-growing middle-income country with potential for huge consumption growth (India) and two that are home to advanced Asian industry (Taiwan and South Korea).image: The EconomistWestern investors looking for exposure to China’s industrial stocks are also turning to Japan, encouraged by its corporate-governance reforms. Last year foreign investors ploughed ¥3trn ($20bn) into Japanese equity funds, the most in a decade. For those with broad mandates, different asset classes are an option. Asia-focused funds investing in real assets, including infrastructure, have grown in popularity.Yet these various alternatives have flaws of their own. Unlike China’s cheap offerings, Indian stocks are expensive. They have higher price-to-earnings ratios than those in other big emerging markets. Although Japan’s stocks look relatively cheap, they make an odd choice for investors seeking rapid income growth. Likewise, Taiwanese and South Korean stocks are included among emerging markets because of the liquidity and accessibility of their exchanges, but both economies are mature high-income ones.Size is a problem, too. Many of the places benefiting as supply chains move away from China are home to puny public markets. Even after fast growth, India’s total market capitalisation runs to just $4trn—not even a third of Hong Kong, Shanghai and Shenzhen combined. When MSCI released its emerging-market index in 1988, Malaysia accounted for a third of its stocks by value. The country now represents less than 2%. Brazil, Chile and Mexico together made up another third; today they make up less than 10%.And whereas returns on Chinese investments tend to follow their own logic, smaller economies are more exposed to the vagaries of the dollar and American interest rates. According to research by UBS Asset Management, Chinese stocks had a correlation of 0.56 with those in the rich world between December 2008 and July 2023 (a score of one suggests the stocks rise and fall in tandem; zero suggests no correlation). By contrast, stocks from emerging markets excluding China had a correlation of 0.84 with rich-world equities.The emergence and growth of funds that pledge to cut out China will make life easier for investors who wish to avoid the world’s second-largest stockmarket. Without a turnaround in the country’s economic fortunes, or a sustained cooling of tensions between Beijing and Washington, interest in such strategies will grow. They will not, however, evoke the sort of enthusiasm investors once felt about China. ■ More

  • in

    Spirit Airlines shares extend rebound after it appeals ruling blocking JetBlue merger

    Spirit Airlines shares jumped Monday after the budget carrier and JetBlue said after the market closed on Friday they would appeal a federal judge’s ruling blocking the airlines’ planned merger
    JetBlue agreed to buy Spirit for $3.8 billion in a 2022 deal that would have created the country’s fifth-largest airline.
    Spirit shares are down about 50% since a U.S. District Court judge blocked the merger.

    Spirit and JetBlue planes at Fort Lauderdale-Hollywood International Airport (FLL) in Fort Lauderdale, Florida, US, on Wednesday, Nov. 1, 2023.
    Eva Marie Uzcategui | Bloomberg | Getty Images

    Spirit Airlines shares jumped about 20% on Monday after the budget carrier and JetBlue said after the market closed Friday that they would appeal a federal judge’s ruling blocking the airlines’ planned merger on antitrust grounds.
    “Our merger agreement with Spirit remains in effect and we still have obligations under the agreement. … This is a standard procedure, required under the merger agreement,” JetBlue General Counsel Brandon Nelson said in a note to staff Friday.

    JetBlue agreed to buy Spirit for $3.8 billion in a 2022 deal that would have created the country’s fifth-largest airline. U.S. District Court Judge William Young last week blocked that combination, citing reduced competition.
    “JetBlue plans to convert Spirit’s planes to the JetBlue layout and charge JetBlue’s higher average fares to its customers,” Young wrote in his Jan. 16 decision. “The elimination of Spirit would harm cost-conscious travelers who rely on Spirit’s low fares.”
    Spirit shares are down more than 45% since that ruling. The stock had dropped more than 60% after the decision but has rebounded slightly following the appeal and after Spirit raised raised its financial forecast for the fourth quarter of 2023. The carrier also said it is looking to refinance its debt.
    JetBlue shares rose about 1% on Monday and have climbed more than 3% since its merger with Sprit was blocked.
    Don’t miss these stories from CNBC PRO: More